S&P 500
5,940.46
-0.4%
-23.14
DJI
42,677.24
-0.3%
-114.83
NASDAQ
$19,142.71
-0.4%
-$72.75
Bitcoin
106,329.00
+1.0%
+1,011.97
AAPL
$206.73
-1.0%
-$2.05
AMZN
$204.08
-1.0%
-$2.08
GOOG
$165.14
-1.6%
-$2.73
META
$636.43
-0.6%
-$4.00
MSFT
$457.90
-0.2%
-$0.97
NVDA
$134.22
-1.0%
-$1.34
TSLA
$343.52
+0.4%
+$1.43
Jan Robison
biostrategy
BSc in Biotechnology, learning finance while traveling Investor's Biker’s style, without the bike.
Recent Articles by Jan Robison
Dec 9, 2013
by Jan Robison
Orexigen Therapeutics: Light at the End of the Tunnel?
Orexigen Therapeutics announces successful interim results for its lead product candidate Contrave followed by the potentially share dilutive announcement of $100 million convertible senior notes offering. Which way should the stock go?
Nov 20, 2013
by Jan Robison
Celgene's Product Portfolio Performance Boosts Valuation Prospects
Celgene, which has almost doubled in value since the begining of the year, reported a strong 3rd quarter performance, raised its EPS guidance for the year and is poised for another exceptional year in 2014.
Nov 11, 2013
by Jan Robison
Seattle Genetics Is Down but Not Out
Seattle Genetics share price has been trending lower lately due to adverse side effects experienced by some patients undergoing clinical trials with the company’s lead product Adcetris. Since long term prospects look bright forSeattle, this could be a nice chance for value investors to enter the stock.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.